Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.

Flora PeyvandiJohnny N MahlanguSteven W PipeCharles R M HayGlenn F PiercePeter KueblerRebecca Kruse-JarresMidori Shima

Published in: Journal of thrombosis and haemostasis : JTH (2021)

No unique risk of death was associated with emicizumab prophylaxis in PwcHA. The data reveal that mortality in PwcHA receiving emicizumab was primarily associated with hemorrhage or non-HA-associated conditions, and was not reported by treaters to be related to emicizumab treatment.

Keyphrases

cardiovascular events
risk factors
electronic health record
genome wide
big data
single cell
gene expression
coronary artery disease
combination therapy
adverse drug
replacement therapy